FY2025 · ended Dec 31, 2025 · Revenue $2.38B, +5.1% YoY · Filed Feb 11, 2026
Royalty Pharma plc (RPRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.4 billion and net income of $770.9 million. As of Sep 30, 2026 it held $894.9 million in cash and investments and $8.6 billion in total debt.
Revenue (TTM)
$2.62B
+11.4% vs year-ago TTM
Net income (TTM)
$672.45M
-12.0% vs year-ago TTM
Operating cash flow (TTM)
$2.96B
+23.1% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$1.41
+5.8% vs year-ago TTM
Dividend per share
$0.84
+5.0% vs prior year
Shares outstanding
—
Net cash
$-7.69B
as of Sep 30, 2026
Operating margin
57.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RPRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1802768
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.3B | $2.4B | $2.2B | $2.3B |
| Operating income | $1.6B | $1.3B | $1.5B | $307.1M | $1.4B |
| Net income | $770.9M | $859.0M | $1.1B | $42.8M | $619.7M |
| Diluted EPS | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 |
| Operating cash flow | $2.5B | $2.8B | $3.0B | $2.1B | $2.0B |
| Total assets | $19.6B | $18.2B | $16.4B | $16.8B | $17.5B |
| Total liabilities | $9.9B | $7.9B | $6.3B | $7.3B | $7.3B |
| Stockholders' equity | $9.7B | $10.3B | $10.1B | $9.5B | $10.2B |
| Cash and investments | $1.1B | $1.7B | $932.4M | $1.9B | $1.8B |
| Total debt | $9.0B | $7.6B | $6.1B | $7.1B | $7.1B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
May 28, 2026 | May 22, 2026 |
All 636 Royalty Pharma plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.